There is some optimism for Alzheimer’s patients thanks to an early phase drug trial.
Alzheimer’s is thought to be caused by the improper buildup of protein plaques and tangles in the brain.
The new drug – Verubecestat – inhibits the enzyme that helps to produce these plaques and tangles.
In trials involving mice the drug was found to significantly reduce markers of plaques and tangles in spinal fluid, as well as reduce the amount of tangles in brain tissue.
Researchers then tested the drug on humans and found it was also effective in reducing markers of Alzheimer’s disease in people but hasn’t yet shown if there is any actual clinical or patient-oriented improvements in outcomes.
The study is published in the journal Science Translational Medicine